

Hutchinson Institute for Cancer Outcomes Research

Cancer Care in Washington State 2023

Dr. Scott Ramsey
Hutchinson Institute for Cancer Outcomes Research (HICOR)

Vision

We believe that every cancer patient should get quality care that meets their goals at a reasonable cost, wherever they live.

Promise of Cancer Care: Technology, Access & Equity

Increasingly realizing the potential of precision medicine



Broader understanding of health-related social needs that impact patient care and outcomes

DIAGNOSIS: DEBT

She was already battling cancer. Then she had to fight the bill collectors npr

July 9, 2022 · 5:00 AM ET Heard on Weekend Edition Saturday

FROM KFF Health News

By Noam Levey



Jeni Rae Peters and daughter embrace at their home in Rapid City, S.D. In 2020, Peters was diagnosed with stage 2 breast cancer. After treatment, Peters estimates that her medical bills exceeded \$30,000.

Challenges Since COVID: What we've heard



Clinics:

- Staffing problems
- Drug shortages
- Financial strains



Payers:

- Declines in recommended screening procedures
- Continued expansion of new, very high- cost therapies



Patients:

- Access difficulties (primary and cancer care)
- Impact of health-related social needs
- Racism
- Financial distress



Everyone:

Leadership turnovers

Challenges Since COVID: What we've heard



Clinics:

- Staffing problems
- Drug shortages
- Financial strains



Payers:

- Declines in recommended screening procedures
- Continued expansion of new, very high- cost therapies



Patients:

- Access difficulties (primary and cancer care)
- Impact of health-related social needs
- Racism
- Financial distress




Everyone:


Leadership turnovers


Is this the new normal or old normal?


What the Data Tells – Community Cancer Care Report











Shout-outs!

Appropriate Therapy (Breast, Colorectal, Lung)



Significant improvement since 1st report:

Northwest Medical Specialties

MultiCare Health System


Top performers, 2023 report:

Northwest Medical Specialties

Providence Regional Cancer Partnership

Providence Health & Services

Appropriate Therapy (Breast Only)



Significant improvement since 1st report:

PeaceHealth

MultiCare Health System

CHI Franciscan

Top performers, 2023 report:

Northwest Medical Specialties

PeaceHealth

Providence Health & Services

Emergency Department Use During Chemo





Top performers, 2023 report:

Northwest Medical Specialties

The Polyclinic

Summit Cancer Centers

Cancer Care Northwest

Inpatient Stays During Chemo



Significant improvement since 1st report:

Osborn Cancer Care


Northwest Medical Specialties

Overlake Medical Center

Top performers, 2023 report:

Providence Regional Cancer Partnership
Northwest Medical Specialties
Yakima Valley Memorial

Breast Cancer Tumor Marker Testing during Surveillance



Significant improvement since 1st report:

CHI Franciscan Health

Northwest Medical Specialties

UW SCCA & Northwest

MultiCare Health System

Top performers, 2023 report:

Virginia Mason

Northwest Medical Specialties

MultiCare Health System

Chemotherapy in Last 14 Days of Life



Significant improvement since 1st report:

Compass Oncology

The Polyclinic

Partner Oncology

Top performers, 2023 report:

Overlake Medical Center

Swedish

Vancouver Clinic

Multiple ED Visits in Last 30 Days of Life



Significant improvement since 1st report: Compass Oncology

Top performers, 2023 report:

PeaceHealth

UW SCCA & Northwest

Confluence Health

ICU Stay in Last 30 Days of Life



Significant improvement since 1st report: Trios Health Providence Regional Cancer Partnership

Top performers, 2023 report: Summit Cancer Centers PeaceHealth Cancer Care Northwest

Hospice at least 3 Days Prior to Death



Significant improvement since 1st report: Olympic Medical Center The Polyclinic Trios Health

Vancouver Clinic Island Hospital **NWMS**

Top performers, 2023 report: PeaceHealth Overlake Medical Center Cancer Care Northwest



Community Cancer Care Report New Quality Metrics!



Community Cancer Care Report New Metrics State-Level Reporting

Biomarker Testing for Metastatic Lung Cancer

Biomarker testing for metastatic lung cancer

Germline Testing

- Germline testing for breast cancer
- Germline testing for ovarian cancer
- Germline testing for pancreatic cancer
- Germline testing for prostate cancer

Timeliness of Care:


Time to start of treatment


Thanks to Steering Committee and Working
Groups for help in prioritizing and developing new
metrics

Thanks to Patients and Patient Advocates for reviewing and refining our reporting

Biomarker Testing at diagnosis for metastatic NSCLC








Fred Hutchinson Cancer Center


Biomarker Testing at diagnosis for metastatic NSCLC





Fred Hutchinson Cancer Center

BRCA1/2 testing for patients with breast cancer

(in first two years following diagnosis)








Fred Hutchinson Cancer Center _____

BRCA1/2 testing for patients with breast cancer


(in first two years following diagnosis)




Fred Hutchinson Cancer Center

Germline testing for patients with ovarian cancer


(in first two years following diagnosis)






Germline testing for patients with pancreatic cancer


(in first two years following diagnosis)






Germline testing for patients with prostate cancer


(in first two years following diagnosis)






Time to start of therapy







Fred Hutchinson Cancer Center


2:

Legend for Figures


5th percentile

75th percentile

Median Number of Days to First Treatment (Metastatic Solid Tumors)



Median Number of Days to First Treatment (Metastatic Lung Cancer)



Cost and Quality Reporting What's next?

Updates to the 2023 Community Cancer Care Report (*Thank you for your feedback*!)

Determine next steps for reporting new measures

Fred Hutchinson Cancer Center

Beyond Reporting Looking Ahead

1. Establishing Priorities

What can we address together as a community?

2. Deciding how we define success

- Improving care delivery?
- Patient Experience?
- Practitioner experience?
- Costs of care?
 - Patient burden
 - System burden

3. Designing and testing new programs





New HICOR Initiative Expand Access to Cancer Research in Washington State



Barriers to Participating in Cancer Research



Patients

- Time and Financial Burden
- Uncertainties about the Experience
- Not offered participation in a trial



Oncology Practices

- Administrative Burden
- Financial burden
- Applicability to the patients or the practice

Less than 1 in 20 cancer patients in WA enroll in a clinical trial.

Is there a better way?







Redefining the Clinical Trial Paradigm for our Community

Build a research program that focuses on improving care and the care experience

- Helping clinics solve challenges
 - Getting the right treatment to the right patient at the right time
 - Reducing practitioner burnout
- Making the journey easier for patients
 - Getting to care: Addressing barriers in the home and the community
 - Ending financial toxicity

Redefining the Clinical Trial Paradigm for our Community (1)

- Build a research program that focuses on improving care and the care experience
 - Helping clinics solve challenges
 - Getting the right treatment to the right patient at the right time
 - Reducing practitioner burnout
 - Making the journey easier for patients
 - · Getting to care: Addressing barriers in the home and the community
 - Ending financial toxicity

Cancer Care Delivery Research

Redefining the Clinical Trial Paradigm for our Community

Make it easier to sponsor and participate in clinical trials

- Easier for Clinics
 - Minimal startup burden
 - Low touch fits into clinic workflow
 - Relevant to the patients they see
 - Makes sense as a business model
- Easier for Patients
 - Simple to understand the study's purpose and if they are eligible
 - Participating is not a burden
 - Experience is a "net positive" no matter the outcome of the study
 - All patients screened and offered participation

Redefining the Clinical Trial Paradigm for our Community

- Make it easier to sponsor and participate in clinical trials
 - Easier for Clinics
 - Minimal startup burden
 - Low touch fits into clinic workflow
 - Relevant to the patients they see
 - Makes sense as a business model
 - Easier for Patients
 - Simple to understand the study's purpose and if they are eligible
 - Participating is not a burden
 - Experience is a "net positive" no matter the outcome of the study
 - All patients screened and offered participation



Pragmatic Studies in Cancer Care Delivery Examples*

A proactive financial navigation intervention to address financial hardship (Randomized Trial)

Remote genomic tumor board intervention versus usual practice (Randomized Trial)

Serum tumor marker directed monitoring versus usual care for metastatic hormone receptor positive HER-2 breast cancer (Randomized Trial)

Automated, guideline-based standing order intervention for colony stimulation factor prescribing (Pragmatic Trial)

Fred Hutchinson Cancer Center

^{*}Cancer Cooperative Group Network Trials

VISION

By 2030, 1 in 5 Washington State cancer patients will be enrolled in a research study.



When we come together, big things happen

We want to hear from you!

We invite members of your organization to meet with us to discuss your cancer research priorities, challenges, and interests.

Using your input, we aim to design studies that are easier for community clinics to implement and for patients to join.

Please contact Karma Kreizenbeck (kkreizen@fredhutch.org) to share your ideas or learn more about this work

Fred Hutchinson Cancer Center